复发性尿路感染症状量表:抗生素治疗反应性与最小临床重要差异
本研究在108例女性复发性尿路感染患者中开展40天纵向随访,评估RUTISS量表对抗生素治疗的反应性并确定MCID。结果显示RUTISS总评分反应性优秀,与PGIC和UTISA强相关,推荐MCID为6.5分,超过测量标准误。RUTISS是首个完全验证的复发性UTI患者报告结局量表。
要点
- RUTISS总评分在基线与治疗第3天间反应性最强(rank-biserial r=0.52)。
- 推荐MCID为6.5分,超过测量标准误。
- RUTISS与PGIC(ρ=0.73)和UTISA(ρ=0.63)强相关。
核心结论
- RUTISS对抗生素治疗反应性优秀,并提供经过验证的MCID(6.5分),可精确解读治疗效果。
研究设计与样本
- 重复测量纵向自然随访研究,纳入108例女性复发性UTI患者(平均年龄53.6岁),随访40天。
主要发现
- RUTISS总评分在所有时间点间反应性优秀,基线与第3天间最强(rank-biserial r=0.52)。
- 与PGIC的Spearman相关系数为0.73,与UTISA为0.63。
- ROC分析显示对检测最小改善的区分度优秀(AUC=0.82)。
- 推荐MCID为6.5分,超过测量标准误。
- 所有子量表显示良好至优秀的反应性。
关键数值与推荐
- 推荐MCID为6.5分。
- 基线与第3天间rank-biserial r=0.52。
- 与PGIC的Spearman ρ=0.73,与UTISA的Spearman ρ=0.63。
- ROC分析AUC=0.82。
临床怎么用
- RUTISS可作为复发性UTI患者症状监测和临床试验的响应性患者中心终点。
- MCID为6.5分有助于临床解读治疗带来的症状改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the responsiveness of the Recurrent Urinary Tract Infection Symptom Scale (RUTISS) to antibiotic treatment and determine the minimal clinically important difference (MCID). METHODS: Female adults with recurrent UTI (N = 108, mean age = 53.6 years) completed a repeated-measures, longitudinal, 40-day naturalistic follow-up study. For participants initiating and completing antibiotic treatment within this period, RUTISS scores were evaluated at baseline (2 days pre-treatment), day 1 of treatment, day 3, and at follow-up (7 days post-treatment). Responsiveness was assessed using effect sizes pre- and post-treatment (rank-biserial correlation), Spearman's rank correlations with anchor measures (Patient Global Impression of Change, PGIC, and UTI Symptom Assessment, UTISA), and receiver operating characteristic analysis. The MCID was triangulated via anchor- and distribution-based methods. RESULTS: The RUTISS total score demonstrated excellent responsiveness between all timepoints and was strongest between baseline and day 3 (rank-biserial r = 0.52), with strong correlations with the PGIC (Spearman's ρ = 0.73) and UTISA (Spearman's ρ = 0.63). Receiver operating characteristic analysis indicated excellent discrimination for detecting even minimal improvement (AUC = 0.82). The recommended MCID was 6.5 points, exceeding the standard error of measurement. All subscales demonstrated good to excellent responsiveness. CONCLUSION: The RUTISS demonstrates excellent responsiveness to antibiotic treatment providing a validated MCID, enabling precise interpretation of treatment effects. As the first fully validated PROM for recurrent UTI, the RUTISS addresses a critical unmet need to assess patient symptom reporting. By providing a responsive and interpretable patient-centered endpoint, the RUTISS enables adequately powered clinical trials and evidence-based symptom monitoring, directly supporting improved patient care and intervention development.
引用
- Newlands AF, Tidmarsh LV, Kramer M, et al. The Recurrent Urinary Tract Infection Symptom Scale: Responsiveness to Antibiotic Treatment and the Minimal Clinically Important Difference. Urology. 2026. PMID: 41579969. doi:10.1016/j.urology.2026.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。